ARCHIVES

In Brief: FDA Opens Advisory Committee Consideration Of NDAs, Finds Discussion Is Not Inhibited

This article is from The Cancer Letter archive.

Vol. 02 No. 37 | September 10, 1976

Download PDF Visit The Full Archive

Related Articles

Kennedy Bill Would Extend Cancer Program Three Years, Kill Budget Bypass

May 4, 1979

Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease

November 30, 2012

Revlimid Maintenance Therapy Delayed Progression by 90%

May 27, 2011

Reinventing NCI: Prevention Program Lacks Leadership, Reorganization Needed, Advisory Group Says

June 20, 1997

Sustained-Release Leuprolide Under Study In Phase III Trial.

June 30, 2000

NCI-Approved Clinical Trials Listed For April 2001

May 25, 2001